Head and neck squamous cell carcinoma (HNSCC) is characterized by aggressive behavior with a propensity for metastasis and recurrence. Here we report a comprehensive analysis of the molecular and clinical features of HNSCC that govern patient survival. We find that TP53 mutation is frequently accompanied by loss of chromosome 3p and that the combination of these events is associated with a surprising decrease in survival time (1.9 years versus >5 years for TP53 mutation alone). The TP53-3p interaction is specific to chromosome 3p and validates in HNSCC and pan-cancer cohorts. In human papillomavirus (HPV)-positive tumors, in which HPV inactivates TP53, 3p deletion is also common and is associated with poor outcomes. The TP53-3p event is modified by mir-548k expression, which decreases survival further, and is mutually exclusive with mutations affecting RAS signaling. Together, the identified markers underscore the molecular heterogeneity of HNSCC and enable a new multi-tiered classification of this disease.
a n a ly s i s worse prognosis than cases with wild-type TP53 (HR = 2.2 ± 0.7; P = 0.03). Among copy number alterations, the most significant association with survival was with heterozygous chromosomal deletions on the 3p arm, which also led to very poor prognosis (HR = 3.5 ± 1.1; Benjamini-Hochbergcorrected P = 0.002; Fig. 1a ). Further analysis of chromosome 3p showed that many cases had a deletion spanning a large fraction of the arm, with increasing frequency of deletion approaching a fragile site in the 3p14.2 region 11 (Supplementary Fig. 3 ). Although general chromosomal instability (CIN), as well as deletion of many individual chromosomal regions, has previously been implicated as diagnostic 1, 12 and prognostic 7,13-15 markers, we found that the 3p event in particular was responsible for the majority of the effect on survival in comparison with global rates of gene deletion (Fig. 1c ).
TP53 and 3p events co-occur and their combination predicts worse clinical outcome
It has previously been shown that genetic alterations often act by redundant or synergistic mechanisms to confer a growth advantage in the tumor 16, 17 . Under the hypothesis that individual events might act in concert, we next examined the 82 prognostic events for pairwise association across the case cohort. This analysis identified 33 pairs of events that were significantly co-occurring or mutually exclusive (Bonferroni-corrected P < 0.01; Supplementary Table 3 ). Among these paired events, a particularly striking finding was that mutation of TP53 and deletion of 3p occurred very frequently together, in 179 of 250 HPV-negative tumors ( Fig. 1d and Table 1 ). Although mutation of TP53 has previously been associated with chromosomal instability 1 , we found that TP53 mutation was associated with 3p loss far more frequently than it was associated with deletions in other chromosomal regions ( Supplementary Fig. 4 and Supplementary  Tables 4-6) . Moreover, the combination of TP53 and 3p events led to worse survival than was predicted by either event independently or additively (Supplementary Fig. 5) . Thus, the synergistic interaction between TP53 and 3p events, with respect to both co-occurrence and survival, supports a clear molecular stratification of HNSCC tumors with and without this combination of events ( Fig. 1c-e , Online Methods, Supplementary Fig. 5 and Supplementary Table 7 ).
We found that the TP53-3p combination of events was associated with advanced tumor stage, although stratification remained prognostic at all stages ( Supplementary Fig. 6 ). Furthermore, the prognostic effect could not be explained by clinical covariates alone and was particularly strong for smokers under 75 years of age (175 cases, the majority of the TCGA cohort) for whom HR was 5.1 for the TP53-3p event relative to individuals without this combination (Online Methods and Supplementary Fig. 7) .
To explore whether the interaction between TP53 mutation and 3p deletion could be replicated in new cases, we obtained 126 additional HPV-negative HNSCC samples that had been deposited in TCGA while our initial study was underway (not included in the 15 January 2014 Firehose run). Although these new cases did not yet have sufficient clinical follow-up data for survival analysis, we indeed observed the same high rate of co-occurrence of TP53 mutation and 3p deletion ( Table 1) . Figure npg a n a ly s i s
We also analyzed clinical follow-up data for 48 HPV-negative HNSCC tumors from the University of Pittsburgh Medical Center 3 for which exome sequencing and copy number profiles had previously been collected after surgery (UPMC cohort; Supplementary  Table 1 ). We observed that, in this cohort, individuals whose tumors contained the TP53-3p aggregate event had substantially worse prognosis than individuals with TP53 mutation alone, confirming the very large effect seen in the TCGA population ( Fig. 2a and Table 1 ). TP53 and 3p events also co-occurred in the UPMC cohort, although with a lower effect size than in the two TCGA cohorts ( Table 1) ; we suspect that this difference in effect size is due to the much higher error rate of DNA sequencing in the earlier UPMC study, which resulted in false negative mutation calls (Online Methods).
We also sought evidence for the TP53-3p combination in cases with HPV-positive tumors, in which the TP53 protein is inactivated via interaction with HPV viral proteins 18, 19 . Analysis of 59 HPV-positive tumors from the TCGA and UPMC cohorts showed that TP53 mutation was very rare in the presence of HPV (odds ratio (OR) = 0.01; P = 1 × 10 −27 by Fisher's exact test), consistent with the expectation that the mutation confers little selective advantage once TP53 is inactivated by HPV. Among the HPV-positive tumors, the 25 tumors with 3p deletion had significantly worse prognosis than the 34 without the 3p event (HR = 5.5 ± 2.6; P = 0.004). This finding lends further support for interaction between TP53 and chromosome 3p with respect to survival and stratifies the growing population of affected individuals with HPV-positive tumors 19 (Fig. 2b) .
Another question was whether the TP53-3p interaction was specific to HNSCC or had broader support across diverse tissues. To address this issue, we performed a pan-cancer analysis based on all publicly available molecular data in TCGA (excluding HNSCC cases), covering 4,404 cases over an additional 17 cancer types 20 (Online Methods). Although these tissues were molecularly heterogeneous and presented with different patient outcomes ( Supplementary Fig. 8a-c) , we nonetheless found compelling evidence for both the co-occurrence and impact on survival of TP53 mutation and 3p deletion in this broader cohort, even when tissue type, patient age and staging were accounted for ( Fig. 2c,d and Table 1 ). npg a n a ly s i s Characterization of subtypes defined by the combined TP53-3p event Finally, we investigated whether the major subtypes defined by TP53 and 3p status ( Fig. 1e ) could be subdivided further by additional molecular markers (Online Methods). Indeed, we found that the 179 cases with the combined TP53-3p event were well stratified by the additional presence of the mir-548k miRNA ( Fig. 3a and Supplementary Fig. 7c ) or mutation of the MUC5B gene ( Fig. 3b and Supplementary Fig. 7d ), both of which were associated with worse prognosis. The gene encoding mir-548k is near CCND1 and FADD at 11q13.3, in a region that is commonly amplified in HNSCC 14 . Very recently, this miRNA has been shown to have oncogenic behavior in esophageal squamous cell carcinoma cell lines 21 . Although we found that 11q13.3 amplification was associated with survival to a lesser degree than mir-548k expression, the prognostic effect seemed to be specific to the expression of the miRNA ( Fig. 3c and Supplementary Fig. 9 ).
Among cases lacking the TP53-3p event combination, we found strong enrichment for mutations affecting caspase-8 as well as RAS and components of RAS signaling ( Table 2 and Supplementary  Fig. 1b) . These enrichments were replicated in the TCGA molecular validation cohort ( Table 2 ). The mutual exclusivity of caspase-8 or RAS events with TP53-3p events provides further support for a TP53-3p-defined subtype, and it implicates alternative routes to tumor progression in the absence of a TP53-3p event.
DISCUSSION
As we approach a full inventory of driver events in cancer 22 , a key next step is to map and decode the complex network of interactions among individual events. Here such an analysis was performed to identify a definitive stratification of head and neck cancer on the basis of the largest tissue bank and data set in existence. We have shown that TP53 mutation, a well-studied driver event that leads to poor survival rates, is nearly always accompanied by specific loss of chromosome 3p ( Fig. 1d and Table 1 ). As has been argued for other cancer-related mutations 17, 23 , the frequent co-occurrence of TP53 and 3p alterations implies a selective advantage of cells acquiring both genomic events. In this study, detection of the TP53-3p interaction was possible owing to the high prevalence of each event individually and the high (marginal) associations with survival rates.
Although our study focused almost entirely on a single compelling interaction, our full analysis uncovered 32 additional interactions in HNSCC that remain to be investigated ( Supplementary Table 3 ). It is likely that this number is an underestimate, as low-frequency and/or non-prognostic events were not evaluated. As cancer cohorts become larger, analyses such as this will become more powered, creating the opportunity to reevaluate the cancer landscape from the perspective of pairwise and, ultimately, higher-order interactions among events.
Our analysis identifies two distinct clinical and molecular paths to cancer in individuals with HPV-negative HNSCC. The first group of cases, characterized by TP53 mutation and loss of the 3p chromosome, is associated with advanced clinical stage and common risk factors such as smoking. This group tends to have very poor outcomes, even when evaluated independently of these risk factors (Supplementary Fig. 7) . The second group of cases, lacking the TP53-3p combination of events, is characterized by mutations affecting RAS signaling and caspase-8 ( Table 2 ) and, ultimately, less aggressive tumors.
Further study is clearly warranted to elucidate the molecular underpinnings of these two groups of cases, with the goal of using such molecular stratification alongside clinical variables to inform patient treatment. Open questions relate to mechanism and the ordering of TP53 and 3p events. For example, what is the factor or factors encoded on chromosome 3p that are responsible for the interaction with TP53? Does one event necessarily precede the other, and is a particular order required for poor survival? It is plausible that genomic instability primed by TP53 mutation gives rise to the loss of the activity of a key factor encoded on chromosome 3p, but other scenarios are possible. Regardless, because the interaction of 3p with TP53 or HPV status is independent of tumor stage, treatment of patients with HNSCC might be modified to coincide with this specific molecular classification. In HPV-negative HNSCC, the need for patient-tailored treatment programs is especially great, as in the current era toxicity of existing regimens has been maximized without necessarily improving outcome in cancers.
Our results also underscore the importance and value of public efforts such as TCGA in gathering, organizing and distributing genomic data. Our work builds on the exemplary TCGA data collection and analysis pipeline 20 to integrate data across different measurement platforms, with the goal of finding higher-order interactions of molecular events. Following the example of TCGA, we have documented and made public all analyses conducted in this study, ranging from data download to processing, exploratory analyses, statistical modeling and visualization (Online Methods). With such a large and complex data set, transparency and reproducibility of analysis are essential to provide a clear understanding of the methodology and to allow for further mining of the results and extension to new data sets.
URLs. Study source code and analysis notebook repository, https:// github.com/theandygross/TCGA/; Broad Firehose, https://confluence.broadinstitute.org/display/GDAC/Home; TCGA Data Portal, https://tcga-data.nci.nih.gov/tcga; UCSC Cancer Genomics Hub, https://cghub.ucsc.edu/.
METHODS

Methods and any associated references are available in the online version of the paper.
Note: Any Supplementary Information and Source Data files are available in the online version of the paper. 
ONLINE METHODS
Availability. All data retrieval and processing steps are documented in a series of IPython notebooks 9 available along with source code online (see URLs). These notebooks provide fully executable instructions for the reproduction of the analyses and the generation of figures and statistics for this study.
Molecular data. Data were obtained from the TCGA Genome Data Analysis Center (GDAC) Firehose website (see URLs) using the firehose_get data-retrieval utility. All data were downloaded from the 15 January 2014 standard data and analyses runs unless otherwise specified. To maintain the coherency of the analysis across different data layers and cancer types, we used Level 3 normalized molecular data as the input to our analysis. The use of the GDAC pipeline is intended to make these results easy to update as more TCGA data become available. For a number of pan-cancer samples, we generated mutation calls from TCGA aligned BAM files obtained from the UCSC Cancer Genomics Hub (see URLs). These calls were only used for cases with sequenced exome data that had yet to go through the Firehose processing pipeline. Somatic mutation calls were made by running the MuTect mutation calling program 24 and the Genome Analysis Toolkit (GATK) SomaticIndelDetector 25 function on targeted regions with default parameters. All steps for downloading and processing these data are documented in the analysis notebooks and accompanying software repository. All mutation calls generated for this analysis are included as Supplementary Table 8 . Although these calls have yet to go through manual curation, we benchmarked this pipeline against TCGA working group mutation calls and found very high overlap with 94% sensitivity and 96% specificity.
Pathway data. Pathway data were downloaded from the Molecular Signatures Database 26 (mSigDB). Version 3 of the canonical pathway gene sets was used for this analysis.
Candidate biomarker construction. Mutation calls were extracted from the annotated MAF files obtained from Firehose and filtered to include only nonsilent mutations. Each case was associated with a binary vector in which each position represented a gene; the position was set to 1 if the gene was observed to harbor one or more mutations in the case and was set to 0 otherwise. Mutation meta-markers were constructed by collapsing the genes within a pathway gene set via a Boolean or operator, such that the pathway was considered altered in a case if any of its genes had a mutation (Supplementary Fig. 1b,c) . Pathway markers that were characterized by a single highly mutated gene or were highly correlated with mutation rate (Mann-Whitney U test P < 0.01) were filtered out.
Copy number aberrations were extracted from the GISTIC2 (ref. 27) processing pipeline included in the standard Firehose analysis run. For biomarker construction, data aggregated on significantly altered lesions (deemed significant at the default 99% confidence settings) were used. mRNA and miRNA expression data were obtained from the Level 3 normalized gene-by-case matrices generated as part of the Firehose analysis pipeline. Data were log 2 transformed. Genes and miRNAs were first filtered on the basis of differential expression, comparing the full set of tumor expression profiles with the 34 profiles available for matched normal tissue (t-test cutoff at P < 0.01). A pattern of background expression was estimated by taking the first principal component of non-differentially expressed genes or miRNAs. This background signal is meant to approximate the most common nontumor-related variation in expression due to inherent properties of the cohort such as population substructure or tissue-specific changes in expression. Realvalued features with high correlation (Pearson's correlation P < 1 × 10 −5 ) to this background expression pattern were filtered out. For the survival analysis, only the top 300 (of a possible 20,502) differentially expressed genes were included in the analysis to limit the burden of multiple-hypothesis correction (all 251 differentially expressed miRNAs were used).
Markers used in this analysis consisted of binary markers and continuousvalued markers. Binary markers were used when expression was only present (having more than 0.5 reads per million) in a moderate fraction of the cohort (between 20 cases and half of the cohort). Real-valued gene and miRNA expression levels were used for differentially expressed features not assigned as binary markers. Gene expression meta-markers were constructed from the loading of the first principal component of the reduced gene-by-case matrix defined by each gene set. Because similarity of gene sets resulted in redundant gene expression meta-markers, marker pairs with high correlation (Spearman's ρ > 0.7) were reduced to a single informative marker by choosing the marker with the greatest differential expression. For the survival analysis, continuous-valued markers were transformed into binary events before testing by setting a threshold that minimized the difference in variance between the resulting two groups. This was used to capture the skew of the distribution and assign the cases on the tail of the expression distribution as having an expression event (Supplementary Fig. 1e ).
Clinical data. Clinical data were downloaded directly from the TCGA Data Portal (see URLs). All outcomes reported relate to all-cause survival. Survival times were censored after 5 years to reduce the confounding effect of patient age. For Figure 2d , survival times were censored after 3 years to show the specific effect within this time window, but all other figures and all statistics cited in the paper used 5-year survival. Although data on comorbidity were limited for this cohort, from other studies, we could estimate the competing mortality within this time frame to be about 20% (refs. 28,29) . We expect the actual effect of such confounding to be minimal, as separation in the survival curves that we observed generally occurred within the first 2 years, during which time we expect non-cancer-associated death rates to be much lower.
For the primary and secondary survival screens, clinical data with missing values were used, but statistics were only calculated on cases with data reported. In multivariate analysis (Supplementary Fig. 7) , missing value indicators were used.
HPV status. HPV calls from sequencing data were obtained from the TCGA HNSCC analysis working group. Owing to the incompleteness of this data set, this information was supplemented with HPV status called from a PCR-based MassARRAY Assay diagnostic provided on the TCGA data portal for cases where sequence-based data were not available.
Prioritization of prognostic events. Feature selection was performed before prognostic event prioritization. Events were selected for which at least 5% of cases were assigned to each group.
Prognostic events (Fig. 1a) were prioritized via a likelihood ratio test comparing a Cox proportional hazards model 30 fit with a candidate biomarker and covariates against a null model fit with the covariates alone. Age and the binary variable of patient age > 75 were used as covariates (both age variables were used to model a nonlinear association of patient age with survival). A correction for multiple-hypothesis testing was employed that uses the method of Benjamini and Hochberg 31 to control for the false discovery rate across the entire pooled space of tested features. After multivariate testing, a univariate log-rank test was assessed for each event, and features with high multivariate significance but low univariate significance (P < 0.05) were filtered from the pool of prognostic events.
As discussed in the text and in Figure 3 , we conducted a second prognostic screen within the 179 cases with the TP53-3p aggregate event. For this analysis, feature construction was repeated, resulting in 1,008 candidate biomarkers (note that this number was higher than in the primary screen owing to more events passing the 5% threshold). During this secondary screen, we found that the year of diagnosis for a patient had a large impact on outcomes. For this reason, we included this variable as a covariate in this screen.
Statistical analysis of TP53-3p interaction on survival.
To assess the role of an interaction term in a statistical model of patient outcomes, we performed leave-one-out cross-validation on a logistic regression model as shown in Supplementary Figure 5 . To convert the survival data into a binary classification problem, we organized patients into two classes depending on whether they were surviving or deceased at t years after surgery. In this analysis, the ratio of deceased to surviving patients was artificially high owing to the ability to observe a death in a shorter follow-up period than the full time interval required to annotate a patient as surviving (i.e., the basis of the Cox censorship problem). To reduce this bias, we removed patients with an observed death but a time of surgery after a set year (2013 − (t − 1)). As the problem was often unbalanced (the number of surviving patients differed from the number of deceased patients), reweighting was performed to give both classes equal weight. A multivariate Cox model fit to the most significant model is also shown in Supplementary Table 7 .
University of Pittsburgh Medical Center cohort. The chromosomal status at 3p was estimated via the median copy number of the 12 genes on the 3p14.2 locus. Matched exome and copy number data were available for 48 of 63 cases with HPV-negative tumors. In preliminary analysis, we found the UPMC cohort to have a significantly lower overall mutation rate than the TCGA cohort, with a median of 73 mutations per case as compared to 104 mutations per case in TCGA (Mann-Whitney U test P < 0.001). This difference can likely be attributed to lower depth of coverage and/or less sophisticated variant calling techniques, as the UPMC study was one of the first large whole-exome molecular cohorts and predates TCGA data collection by about 2 years.
Pan-cancer analysis. Pan-cancer data were downloaded and processed in the same manner as the HNSCC cohort. The chromosomal status at 3p was estimated via the median copy number of the 12 genes on the 3p14.2 locus.
To limit the heterogeneity of the pan-cancer cohort such that differences in molecular characteristics could be assessed, we performed a number of preprocessing steps. This processing reduced the cohort from 7,081 to 4,404 cases appropriate for survival analysis through the following filters:
(1) Only primary tumors were used for all cases; metastatic tumors were discarded. (2) Glioblastoma cases were excluded owing to the extremely low survival rate (5-year survival of 6%).
